Treating Newly Diagnosed Metastatic NSCLC with No Actionable Mutations in the First Line
July 25th 2024Isabel Preeshagul, DO, MBS, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment practices for newly diagnosed patients with metastatic non–small cell lung cancer (NSCLC) and no actionable mutations.
The Role of MRD Testing in Guiding Treatment in R/R MM: ASCO 2024 Updates from PERSEUS
July 19th 2024Following ASCO 2024, Samer Al'Hadidi, MD, discusses recent updates from the PERSEUS trial evaluating the role of testing for minimal residual disease (MRD) in guiding treatment for relapsed/refractory multiple myeloma.